Companies /Healthcare

QuidelOrtho Corporation

NASDAQ: QDEL Medical Devices
$9.87
▼ $0.34 (−3.33%) today
Markets closed · 9:58pm ET

24/7 Wall St. View

QDEL at a Glance

Valuation
Market cap
$700.5M
Profitability
Revenue (TTM)
$2.6B
Profit margin
-14.2%
EPS (TTM)
$-5.39
Price
52-week range
$10 – $36
24/7 target
$14.42
Street target
$15.00
Earnings
Next report
Feb 9, 2027

Headquartered in San Diego, CA Fiscal year ends December NASDAQ: QDEL quidelortho.com

About QuidelOrtho

QuidelOrtho Corporation (Nasdaq: QDEL) develops, manufactures and sells in vitro diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing. Its products serve settings from the point of care to hospitals, clinical labs and clinics. Revenue is reported across:
- **Labs:** clinical chemistry and immunoassay systems and consumables supported by a large global installed base.
- **Immunohematology:** blood typing and transfusion diagnostics.
- **Point of Care:** rapid tests, including respiratory diagnostics whose demand is seasonal.
- **Molecular Diagnostics.**
- **Donor Screening:** the U.S. business has declined sharply.

The company relies on recurring reagent and consumable sales tied to its instrument base. It has meaningful exposure to China, where In Vitro Diagnostics pricing changes and reimbursement cuts by the China National Health Security Administration are pressuring sales. In the third quarter of 2026 it launched a cost transformation and enterprise restructuring program to reorganize into two focused businesses, Core Diagnostics and Point of Care Diagnostics, targeting over $80 million in annual savings in 2027. Updated

Latest Activity

QDELQuidelOrtho
Q3 2026
EPS
$0.31
est $0.18+73.8%
Revenue
$619M
est $628M-1.4%

A 27.3% drop in Point of Care revenue, driven by China pricing reforms and a soft respiratory season, pushed management into an enterprise restructuring targeting more than $80 million in annual savings by 2027. Full-year adjusted EPS guidance narrowed to $0.65 to $0.70.

Quarterly EPS — reported vs estimate

QDEL Coverage

Frequently Asked Questions

What does QuidelOrtho do?

QuidelOrtho Corporation (Nasdaq: QDEL) develops, manufactures and sells in vitro diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing. Its products serve settings from the point of care to hospitals, clinical labs and clinics.

What is the QDEL stock price target?

24/7 Wall St.'s 12-month price target for QDEL is $14.42, rated Buy. The Wall Street consensus target is $15.00. QDEL price prediction →